PortalPublikationenPrognostic Impact of Serum Free Light Chain Ratio Normalizat...

Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial

Standard

Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial. / Klein, Eva-Maria; Tichy, Diana; Salwender, Hans J; Mai, Elias K; Duerig, Jan; Weisel, Katja C; Benner, Axel; Bertsch, Uta; Akhavanpoor, Mabast; Besemer, Britta; Munder, Markus; Lindemann, Hans-Walter; Hose, Dirk; Seckinger, Anja; Luntz, Steffen; Jauch, Anna; Elmaagacli, Ahmet; Fuhrmann, Stephan; Brossart, Peter; Goerner, Martin; Bernhard, Helga; Raab, Marc S; Blau, Igor W; Haenel, Mathias; Scheid, Christof; Goldschmidt, Hartmut; On Behalf Of The German-Speaking Myeloma Multicenter Group Gmmg.

in: CANCERS, Jahrgang 13, Nr. 19, 28.09.2021, S. 4856.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Klein, E-M, Tichy, D, Salwender, HJ, Mai, EK, Duerig, J, Weisel, KC, Benner, A, Bertsch, U, Akhavanpoor, M, Besemer, B, Munder, M, Lindemann, H-W, Hose, D, Seckinger, A, Luntz, S, Jauch, A, Elmaagacli, A, Fuhrmann, S, Brossart, P, Goerner, M, Bernhard, H, Raab, MS, Blau, IW, Haenel, M, Scheid, C, Goldschmidt, H & On Behalf Of The German-Speaking Myeloma Multicenter Group Gmmg 2021, 'Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial', CANCERS, Jg. 13, Nr. 19, S. 4856. https://doi.org/10.3390/cancers13194856

APA

Klein, E-M., Tichy, D., Salwender, H. J., Mai, E. K., Duerig, J., Weisel, K. C., Benner, A., Bertsch, U., Akhavanpoor, M., Besemer, B., Munder, M., Lindemann, H-W., Hose, D., Seckinger, A., Luntz, S., Jauch, A., Elmaagacli, A., Fuhrmann, S., Brossart, P., ... On Behalf Of The German-Speaking Myeloma Multicenter Group Gmmg (2021). Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial. CANCERS, 13(19), 4856. https://doi.org/10.3390/cancers13194856

Vancouver

Klein E-M, Tichy D, Salwender HJ, Mai EK, Duerig J, Weisel KC et al. Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial. CANCERS. 2021 Sep 28;13(19):4856. https://doi.org/10.3390/cancers13194856

Bibtex

@article{9199fe4673da4c0d95bfebe4f6da78b1,
title = "Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial",
abstract = "We investigated the prognostic impact of time-dependent serum free light chain ratio (FLCr) normalization in 590 patients with secretory multiple myeloma (MM) during first-line treatment within the German-Speaking Myeloma Multicenter Group MM5 trial. Serum free light chains (sFLC) were assessed by the Freelite test at baseline, after induction, mobilization, autologous blood stem cell transplantation, consolidation and every three months during maintenance or follow up within two years after the start of maintenance. The proportion of patients with a normal or normalized FLCr increased from 3.6% at baseline to 23.2% after induction and 64.7% after consolidation. The achievement of FLCr normalization at any one time before the start of maintenance was associated with significantly prolonged progression-free survival (PFS) (p < 0.01, hazard ratio (HR) = 0.61, 95% confidence interval (95% CI) = 0.47-0.79) and overall survival (OS) (p = 0.02, HR = 0.67, 95% CI = 0.48-0.93) in multivariable time-dependent Cox regression analyses. Furthermore, reaching immune reconstitution, defined as the normalization of uninvolved immunoglobulins, before maintenance was associated with superior PFS (p = 0.04, HR = 0.77, 95% CI = 0.60-0.99) and OS (p = 0.01, HR = 0.59, 95% CI = 0.41-0.86). We conclude that FLCr normalization during therapy is an important favorable prognostic factor in MM. Therefore, we recommend serial measurements of sFLC during therapy until achieving FLCr normalization, even in patients with secretory MM.",
author = "Eva-Maria Klein and Diana Tichy and Salwender, {Hans J} and Mai, {Elias K} and Jan Duerig and Weisel, {Katja C} and Axel Benner and Uta Bertsch and Mabast Akhavanpoor and Britta Besemer and Markus Munder and Hans-Walter Lindemann and Dirk Hose and Anja Seckinger and Steffen Luntz and Anna Jauch and Ahmet Elmaagacli and Stephan Fuhrmann and Peter Brossart and Martin Goerner and Helga Bernhard and Raab, {Marc S} and Blau, {Igor W} and Mathias Haenel and Christof Scheid and Hartmut Goldschmidt and {On Behalf Of The German-Speaking Myeloma Multicenter Group Gmmg}",
year = "2021",
month = sep,
day = "28",
doi = "10.3390/cancers13194856",
language = "English",
volume = "13",
pages = "4856",
journal = "CANCERS",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "19",

}

RIS

TY - JOUR

T1 - Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial

AU - Klein, Eva-Maria

AU - Tichy, Diana

AU - Salwender, Hans J

AU - Mai, Elias K

AU - Duerig, Jan

AU - Weisel, Katja C

AU - Benner, Axel

AU - Bertsch, Uta

AU - Akhavanpoor, Mabast

AU - Besemer, Britta

AU - Munder, Markus

AU - Lindemann, Hans-Walter

AU - Hose, Dirk

AU - Seckinger, Anja

AU - Luntz, Steffen

AU - Jauch, Anna

AU - Elmaagacli, Ahmet

AU - Fuhrmann, Stephan

AU - Brossart, Peter

AU - Goerner, Martin

AU - Bernhard, Helga

AU - Raab, Marc S

AU - Blau, Igor W

AU - Haenel, Mathias

AU - Scheid, Christof

AU - Goldschmidt, Hartmut

AU - On Behalf Of The German-Speaking Myeloma Multicenter Group Gmmg, null

PY - 2021/9/28

Y1 - 2021/9/28

N2 - We investigated the prognostic impact of time-dependent serum free light chain ratio (FLCr) normalization in 590 patients with secretory multiple myeloma (MM) during first-line treatment within the German-Speaking Myeloma Multicenter Group MM5 trial. Serum free light chains (sFLC) were assessed by the Freelite test at baseline, after induction, mobilization, autologous blood stem cell transplantation, consolidation and every three months during maintenance or follow up within two years after the start of maintenance. The proportion of patients with a normal or normalized FLCr increased from 3.6% at baseline to 23.2% after induction and 64.7% after consolidation. The achievement of FLCr normalization at any one time before the start of maintenance was associated with significantly prolonged progression-free survival (PFS) (p < 0.01, hazard ratio (HR) = 0.61, 95% confidence interval (95% CI) = 0.47-0.79) and overall survival (OS) (p = 0.02, HR = 0.67, 95% CI = 0.48-0.93) in multivariable time-dependent Cox regression analyses. Furthermore, reaching immune reconstitution, defined as the normalization of uninvolved immunoglobulins, before maintenance was associated with superior PFS (p = 0.04, HR = 0.77, 95% CI = 0.60-0.99) and OS (p = 0.01, HR = 0.59, 95% CI = 0.41-0.86). We conclude that FLCr normalization during therapy is an important favorable prognostic factor in MM. Therefore, we recommend serial measurements of sFLC during therapy until achieving FLCr normalization, even in patients with secretory MM.

AB - We investigated the prognostic impact of time-dependent serum free light chain ratio (FLCr) normalization in 590 patients with secretory multiple myeloma (MM) during first-line treatment within the German-Speaking Myeloma Multicenter Group MM5 trial. Serum free light chains (sFLC) were assessed by the Freelite test at baseline, after induction, mobilization, autologous blood stem cell transplantation, consolidation and every three months during maintenance or follow up within two years after the start of maintenance. The proportion of patients with a normal or normalized FLCr increased from 3.6% at baseline to 23.2% after induction and 64.7% after consolidation. The achievement of FLCr normalization at any one time before the start of maintenance was associated with significantly prolonged progression-free survival (PFS) (p < 0.01, hazard ratio (HR) = 0.61, 95% confidence interval (95% CI) = 0.47-0.79) and overall survival (OS) (p = 0.02, HR = 0.67, 95% CI = 0.48-0.93) in multivariable time-dependent Cox regression analyses. Furthermore, reaching immune reconstitution, defined as the normalization of uninvolved immunoglobulins, before maintenance was associated with superior PFS (p = 0.04, HR = 0.77, 95% CI = 0.60-0.99) and OS (p = 0.01, HR = 0.59, 95% CI = 0.41-0.86). We conclude that FLCr normalization during therapy is an important favorable prognostic factor in MM. Therefore, we recommend serial measurements of sFLC during therapy until achieving FLCr normalization, even in patients with secretory MM.

U2 - 10.3390/cancers13194856

DO - 10.3390/cancers13194856

M3 - SCORING: Journal article

C2 - 34638344

VL - 13

SP - 4856

JO - CANCERS

JF - CANCERS

SN - 2072-6694

IS - 19

ER -